Showcasing ADVM-022 as a Treatment for Neovascular AMD

Time: 9:30 am
day: Day Two

Details:

  • Wet AMD: the rationale for using gene therapy for treatment
  • Utilizing aAV.7m8 vector for intravitreal administration and preclinical and clinical
    support for dosing
  • Clinical experience with ADVM-022 in Wet AMD

Speakers: